Voyager Therapeutics, Inc. (VYGR)
Largest Insider Buys in Sector
VYGR Stock Price History Chart
VYGR Stock Performance
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; and Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear …
Insider Activity of Voyager Therapeutics, Inc.
Over the last 12 months, insiders at Voyager Therapeutics, Inc. have bought $0 and sold $379,660 worth of Voyager Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Voyager Therapeutics, Inc. have bought $20.58M and sold $3.83M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 4,395,588 shares for transaction amount of $39.03M was made by NEUROCRINE BIOSCIENCES INC (10 percent owner) on 2023‑02‑23.
List of Insider Buy and Sell Transactions, Voyager Therapeutics, Inc.
| 2024-10-02 | Sale | Chief Legal Officer | 5,999 0.0109% | $5.82 | $34,914 | +20.36% | ||
| 2024-04-02 | Sale | President and CEO | 12,115 0.0222% | $9.86 | $119,454 | -21.39% | ||
| 2024-04-02 | Sale | Chief Operating Officer | 1,357 0.0025% | $9.88 | $13,407 | -21.39% | ||
| 2024-02-21 | Sale | President and CEO | 13,033 0.0278% | $7.46 | $97,226 | +6.02% | ||
| 2024-02-21 | Sale | Chief Financial Officer | 3,764 0.008% | $7.46 | $28,079 | +6.02% | ||
| 2024-02-21 | Sale | Chief Operating Officer | 3,966 0.0084% | $7.45 | $29,547 | +6.02% | ||
| 2024-02-21 | Sale | Chief Scientific Officer | 3,365 0.0072% | $7.47 | $25,137 | +6.02% | ||
| 2024-02-20 | Sale | Chief Scientific Officer | 602 0.0013% | $7.68 | $4,623 | +6.94% | ||
| 2024-01-17 | Sale | Chief Operating Officer | 2,543 0.0054% | $7.15 | $18,182 | +7.44% | ||
| 2024-01-17 | Sale | Chief Scientific Officer | 1,266 0.0027% | $7.18 | $9,090 | +7.44% | ||
| 2023-10-03 | Sale | Chief Financial Officer | 13,567 0.0298% | $6.99 | $94,833 | +9.57% | ||
| 2023-09-15 | Sale | Chief Scientific Officer | 10,500 0.0245% | $8.16 | $85,680 | -2.64% | ||
| 2023-07-06 | Sale | Chief Scientific Officer | 5,500 0.0137% | $10.80 | $59,400 | -22.70% | ||
| 2023-06-30 | Sale | Chief Scientific Officer | 5,000 0.0123% | $11.41 | $57,050 | -28.03% | ||
| 2023-04-03 | Sale | President and CEO | 7,437 0.0187% | $7.83 | $58,232 | +2.19% | ||
| 2023-04-03 | Sale | Chief Operating Officer | 1,259 0.0032% | $7.83 | $9,858 | +2.19% | ||
| 2023-03-15 | Sale | Chief Operating Officer | 15,373 0.041% | $8.20 | $126,059 | +0.25% | ||
| 2023-02-23 | 10 percent owner | 4.4M 14.7056% | $8.88 | $39.03M | +14.60% | |||
| 2023-02-17 | Sale | Senior VP & General Counsel | 3,297 0.0086% | $7.45 | $24,563 | +6.59% | ||
| 2023-02-17 | Sale | Chief Scientific Officer | 738 0.0019% | $7.45 | $5,498 | +6.59% |
Insider Historical Profitability
| NEUROCRINE BIOSCIENCES INC | 10 percent owner | 8575316 15.6983% | $5.44 | 2 | 0 | +7.07% |
| EcoR1 Capital, LLC | director | 3851507 7.0507% | $5.44 | 1 | 3 | +28.87% |
| Sanofi | 2477941 4.5362% | $5.44 | 1 | 0 | <0.0001% | |
| PAUL STEVEN M | President and CEO | 872351 1.597% | $5.44 | 1 | 0 | <0.0001% |
| GERAGHTY JAMES A | director | 76588 0.1402% | $5.44 | 2 | 0 | <0.0001% |
Institutional Investor Ownership
| Armistice Capital Llc | $43.5M | 8.59 | 4.67M | +10.29% | +$4.06M | 0.14 | |
| BlackRock | $40.94M | 8.08 | 4.4M | +67.03% | +$16.43M | <0.01 | |
| Ecor1 Capital Llc | $36.47M | 7.2 | 3.92M | +1.72% | +$614,823.09 | 0.26 | |
| The Vanguard Group | $30.09M | 5.94 | 3.23M | +27.75% | +$6.54M | <0.01 | |
| Farallon Capital | $21.34M | 4.21 | 2.29M | +77.4% | +$9.31M | 0.15 |